On Target for 400m Tonnes of Decarbonisation - Carbon13 Closes Successful Seed Round of Over $2.2m
20.7.2023 09:33:00 EEST | Business Wire | Press release
Carbon13, the venture builder for the climate emergency, is today announcing the close of its latest seed round, resulting in over $2.2m.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230719330116/en/
L-R, Jonathan Cumming, Chief Financial Officer & Managing Director, Dr Chris Coleridge, Founder & CEO, Dr Nicky Dee, Co-founder & Chief Sustainability and Innovation Officer, Michael Langguth, Co-founder & Chief Strategy Officer (Photo: Business Wire)
The new funding is set to boost Carbon13’s operations significantly and propel Carbon13’s current and future ventures towards the key target of 400 million tonnes of decarbonisation.
The successful funding round was made possible thanks to a range of family offices and venture firms, including True Ventures, a Silicon Valley-based venture capital firm focused on early stage technology startups.
The new injection of funding for Carbon13 will enable a significant increase in climate startup production and a scaling of ambition. Currently, Carbon13 ventures possess an annual mitigation potential of over 420 million tonnes of CO2e – this potential is now set to rise further, as is the number of invested ventures built through Carbon13 programmes since 2021 (currently 46).
In addition, since 2021, Carbon13 has now supported over 350 startup founders through its three programmes (Venture Builder Europe, Venture Builder UK, and Venture Launchpad). This number is also set to grow significantly thanks to the new funding. By end of 2025, Carbon13's Venture Builder is on course to support over 1,000 entrepreneurs to build at least 200 startups.
Commenting on the successful funding round, CEO and Founder of Carbon13, Chris Coleridge, said: “This investment from True Ventures and four family offices is crucial to Carbon13’s plans for scaling our support to entrepreneurs tackling the most urgent global challenges in decarbonisation and carbon capture.
Climate change is not just a scientific challenge, it is not just a business innovation challenge, it is also a people challenge. We have found that remarkable things happen when you bring together some of the world’s most talented people who are all highly motivated by the mission to fight the climate emergency. True's investment is therefore a valuable recognition of our people-first approach.
I'm also delighted that Carbon13 is joining True's community of decarbonisation startups. Launching and scaling ventures with credible claims to significant emissions mitigation was a foundational principle when I was developing Carbon13 with my cofounders. Again, it is our people-first approach which drives this, as our programmes inculcate carbon intelligence within the founding team to empower them to make strategic decisions based as much on carbon reduction as on commercial value. Ultimately, in the world of Net Zero 2050, there will be no distinction between the two.”
Also commenting, Priscilla Tyler, Vice President at True Ventures, said: “Our investment in Carbon13 and its focused support of carbon-neutralizing technology is an incredible complement to our portfolio of climate tech investments. What’s more, the Carbon13 team aligns deeply with our values and belief in the creative entrepreneur. They invest in people first and tech second. We’re thrilled for this partnership and to help embolden their important work around mitigating climate change.”
- ENDS -
About Carbon13
Carbon13 is the Venture Builder for the Climate Emergency. Since 2021, three programmes of the Venture Builder Europe, Venture Builder UK, and Venture Launchpad, have invested in 46 startups, and worked with over 350 founders. Carbon13 grew out of the Cambridge ecosystem of technology, academia and innovation, and has expanded to Berlin, our new base in the EU. Notable Carbon13 alumni include Kita, Infyos, Nium, Biozeroc, Materials Nexus and Tierra Foods. Kita and Tierra Foods are both nominated for Earthshot 2023 prizes.
Carbon13 media pack available here: https://carbonthirteen.com/media/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719330116/en/
Contact information
PR and enquiries
contact
Dark Green PR
Tel: +44 (0)7940 968704
team@darkgreenpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom